focus -WSS

focus

author：knowledge 2025-09-09 19:28:26 - browse：717

Sen. Rand Paul (C) (R-KY) questions Homeland Security Secretary Alejandro Mayorkas and FBI Director Christopher Wray during a hearing held by the Senate Homeland Security and Governmental Affairs Committee October 31, 2023 in Washington, DC. — Sen. Rand Paul (R-Ky.) Win McNamee/Getty Images

WASHINGTON — A Senate panel Wednesday passed a bill aimed at preventing certain Chinese companies from doing business in the United States. The sole no vote was by Sen. Rand Paul (R-Ky.), who worries that Congress is using anger toward China as a cover for advancing parochial interests.

Many in Congress are worried the Chinese government and military are using the rising dominance of national companies to gather Americans’ genetic information, which could be used for reasons that range from creating bioweapons to giving China a leg up in drug development.

The Biosecure Act, by Homeland Security and Governmental Affairs Chair Gary Peters (D-Mich.), is a response to those concerns. The bill would block the U.S. government from contracting with companies that do business with Chinese “biotechnology companies of concern,” and it names four companies that must be on that list: BGI Genomics, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of these companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： The problem with charging patients to message their doctors

entertainment

WSS

Sen. Paul opposes bill to ban Chinese biotechs

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Change Healthcare cyberattack prompts Medicare loan program

Warren pushes Witty on UnitedHealth's control over physicians

Sepsis can kill a child within hours. Here's how hospitals are fighting back

In his State of the Union, Biden takes clear aim at 'Big Pharma'

knowledge

focus

hotspot

In age of alternative facts, a scholarly course on calling out crap

Crowdfunding for medical bills sidesteps core problem, author says

FDA approval of Sarepta Duchenne genetic therapy gives me hope

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Moonlake's readout produced a cash windfall. Risks remain

Novel spinal cord stimulator treats paralysis without surgery

Cancer drug shortages should be causing more outrage

Is it ever OK for doctors to lie to their patients?

ChatGPT in medicine: STAT answers readers' burning questions

Most antidepressants don't work on kids, teens, study finds

focus

Just how do doctors, lawmakers, and the public define abortion?

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Brain technologies pose threats that are all too real, experts warn

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Amylyx ALS drug failure raises questions and concerns

First medicine developed to treat MASH expected to be approved soon

entertainment

Wikipedia

focus

knowledge